Skip to main content

Table 2 Details on average costs per infusion and per hospital day, respectively, for outpatients and inpatients. Percentages are rounded and are for guidance only

From: Does the introduction of an infliximab biosimilar always result in savings for hospitals? A descriptive study using real-world data

Cohort

Patients n (%)

Costs mean (sd) [CHF/inf./HD]

Costs mean (PCI) [CHF/inf./HD]

Outpatients

255 (100)

4 991 (6 931)

Started OI and maintained OI

76 (30)

5 351 (10 225)

(3 458 ; 7 942)

Started CT-P13 and maintained CT-P13

43 (17)

3 317 (2 681)

(2 566 ; 4 135)

Started OI and discontinued OI

19 (7)

3 276 (3 083)

(2 044 ; 4 732)

Started CT-P13 and discontinued CT-P13

31 (12)

5 379 (6 387)

(3 431 ; 7 839)

Switched from OI to CT-P13 and maintained CT-P13

54 (21)

5 966 (5 573)

(4 562 ; 7 489)

Switched from OI to CT-P13 and discontinued CT-P13

16 (6)

3 407 (1 612)

(2 657 ; 4 205)

Switched from OI to CT-P13 and switched back to OI

16 (6)

7 359 (6 350)

(4 462 ; 10 413)

Inpatients

94 (100)

1 611 (1 020)

Started OI and maintained OI

27 (29)

2 033 (1 096)

(1 641 ; 2 440)

Started CT-P13 and maintained CT-P13

22 (23)

1 457 (747)

(1 176 ; 1 781)

Started OI and discontinued OI

6 (6)

1 439 (453)

(1 088 ; 1 743)

Started CT-P13 and discontinued CT-P13

21 (22)

1 267 (767)

(968 ; 1 612)

Switched from OI to CT-P13 and maintained CT-P13

8 (9)

1 727 (1 748)

(671 ; 2 917)

Switched from OI to CT-P13 and discontinued CT-P13

7 (7)

1 134 (855)

(585 ; 1 764)

Switched from OI to CT-P13 and switched back to OI

3 (3)

2 513 (1 236)

(1 547 ; 3 905)

  1. HD Hospital day, inf. Infusion, OI Originator infliximab, PCI Percentile confidence intervals, sd standard deviation